Jiangsu Canopus Wisdom Medical Technology Co (301290) Fair Value & Analysis
Healthcare · CN · Market cap 2.9B CNY
Fair value as of: Jul 9, 2026
From 13 valuation models · updated 32 days ago
Share price +8.5% over the past month.
A solid business, but screening 75% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥10.27). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥5.01 to ¥10.27) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
44‑month range ¥16.42 – ¥49.12 · fair‑value band ¥5.01 – ¥10.27 · the ¥29.08 price screens above the ¥7.15 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Jiangsu Canopus Wisdom Medical Technology Co (301290) currently trades at ¥29.08, while our model-based Fair Value estimate is ¥7.15, implying the stock looks roughly 75.4% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Jiangsu Canopus Wisdom Medical Technology Co generated revenue of 3.9B CNY at a net margin of 6.2%. Revenue grew 15.7% year over year. It earns a return on equity of 10.9%. Net debt stands at 37.5M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥5.01 (bear case) to ¥10.27 (bull case); at ¥29.08, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 22% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -75%, 301290 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (¥14.36) versus Earnings-Based (¥5.27). Highest evidence: Growth DCF (72).
Notify me when 301290 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. engages in the research, development, manufacturing, and sale of surgical medical devices, staplers, and spare parts in China.
Full company description
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. engages in the research, development, manufacturing, and sale of surgical medical devices, staplers, and spare parts in China. It offers orthopedic traction frames, surgical lamps, hospital system integration solutions, electric gynecological examination tables, obstetrics and gynecology examination tables, electric operating tables, multi-functional intelligent operating tables, ventilators, surgical endoscopes, ultrasound equipment, hydrogen peroxide low-temperature plasma sterilizers, and multifunctional monitoring modules; medical consumables; and open stapler surgical equipment, such as linear cutting stapler, tubular stapler, and hemorrhoidal stapler. The company also provides surgical equipment, such as monitor stands, endoscope compound arm pendant, compound arm crane, dry and wet separation suspension bridges, hanging columns, electric endoscope pendant, cavity mirror hanging towers, cavity mirror pendant towers, and electric delivery beds. It also exports its products to Europe, South America, Southeast Asia, the Middle East, and Africa. The company was founded in 2001 and is based in Changzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Canopus Wisdom Medical Technology Co reported revenue of ¥387M in FY2025 versus ¥446M in FY2021, a compound −3.5%/yr. Reported net income was −¥37.9M in FY2025.
301290 screens 75% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Jiangsu Canopus Wisdom Medical Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangsu Canopus Wisdom Medical Technology Co (301290) overvalued or undervalued?
What is the fair value of 301290?
What is the quality score of 301290?
What is the revenue of Jiangsu Canopus Wisdom Medical Technology Co (301290)?
What is the net profit margin of 301290?
Does Jiangsu Canopus Wisdom Medical Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangsu Canopus Wisdom Medical Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.